Event-Level Narrative

Slides:



Advertisements
Similar presentations
Safety Reporting IN Clinical Trials
Advertisements

Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
ADVERSE EVENT REPORTING
Statistical Analysis Plan and Clinical Study Report
Focused on Pulmonology and Hepatology
Elke Sennewald Berlin, 28 September 2010 CDASH Tutorial.
Copyright © 2013, SAS Institute Inc. All rights reserved. LEVERAGE THE CDISC DATA MODEL TO STREAMLINE ANALYTICAL WORKFLOWS KELCI J. MICLAUS, PH.D. RESEARCH.
An Introduction to Clinical Data Acquisition Standards Harmonization (CDASH) Loryn Thorburn © 2010 PAREXEL International | Confidential.
Managing Sponsorship Research Services University of Oxford.
Bay Area CDISC Implmentation Network – July 13, 2009 How a New CDISC Domain is Made Carey Smoak Team Leader CDISC SDTM Device Team.
23 August 2015Michael Knoessl1 PhUSE 2008 Manchester / Michael Knoessl Implementing CDISC at Boehringer Ingelheim.
JumpStart the Regulatory Review: Applying the Right Tools at the Right Time to the Right Audience Lilliam Rosario, Ph.D. Director Office of Computational.
© 2011 Octagon Research Solutions, Inc. All Rights Reserved. The contents of this document are confidential and proprietary to Octagon Research Solutions,
Generate Web-based Clinical Reporting System (e-CRS) Jianquan Wang Department of Computer Science Ball State University October 16, 2000.
Qualification Process for Standard Scripts Hosted in the Open Source Repository ABSTRACT Dante Di Tommaso 1 and Hanming Tu 2 Tehran 1 F. Hoffmann-La Roche.
CDASh : A Primer and Guide to Implementation
1CDISC 2002 RCRIM – Standard Domains Agenda NCI Presentation Standard Domains Working Group Goals Introduction to FDA Information Model (FIM) Discussion:
Page 1. July 2005 Page 2 Type search terms into box on the main page. Tutorial. Save searches in My NCBI ‘cubby.’ Enter PubMed by double- clicking in.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.
Investigator’s Meeting
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Updates on CDISC Activities
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
How Good is Your SDTM Data? Perspectives from JumpStart Mary Doi, M.D., M.S. Office of Computational Science Office of Translational Sciences Center for.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
CONFIDENTIAL © 2012 | 1 Writing a Statistical Analysis Plan DIA Medical Writing SIAC July 12, 2012 Peter Riebling, MS, RAC Associate Director, Regulatory.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
CLINICAL TRIALS.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Exposure adjustment in Risk-based monitoring in clinical trials with
Responsibilities of Sponsor, Investigator and Monitor
FHIR Adverse Event Resource
De-Identification Standards for CDISC Data Models
score (see methods section, phase 3)
WorldVistA EHR (VOE) CCHIT Certified EHR.
Within Trial Decisions: Unblinding and Termination
Pharmacovigilance in clinical trials
Secondary Uses Primary Use EHR and other Auhortities Clinical Trial
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Clinical Study Results Publication
*Continue on SAE supplemental page CTT21 A if more space is required
Why use CDISC for trials not submitted to regulators?
Intervista a Cesare Gridelli
Predictive Modeling for Patient Recruitment in Multicenter Trials
In-Depth Report from Optimizing Data Standards Working Group
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
SDTMs in Medical Devices A First Attempt
Authors Institution(s)
Statistical Programming
WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?
Visualizing Subject Level Data in Clinical Trial Data
S B A R SBAR Information Tool
Contemporary Evidence-Based Guidelines
Safety issues in the development of treatments for osteoarthritis: recommendations of the Safety Considerations Working Group  V. Strand, D.A. Bloch,
Module 6 Part B: Internet Resources
Model Enhanced Classification of Serious Adverse Events
Safety analysis of clinical trials in NDA submissions JSM 2018, Jul
Safety Analytics Workshop – Computational Science Symposium 2019
Adverse Event Reporting _____________________________
Dr Tim England TICH-2 SAE adjudicator
Table of Contents – Part B
Natasa Rajicic, ScD July 31, 2019
Presentation transcript:

Event-Level Narrative Efficient Safety Assessment in Clinical Trials Using the Computer-Generated AE Narratives of JMP Clinical Richard C. Zink & Drew Foglia JMP Life Sciences, SAS Institute Background Challenges Event-Level Narrative ICH Guideline E3 on the content of clinical study reports (CSRs) recommends that sponsors provide written narratives describing each death, serious adverse event (SAE), and other significant AE of special interest to the disease under investigation. Narratives may shed light on factors associated with severe events, or describe effective means for managing patients for appropriate recovery. We describe how AE narratives can be generated directly from study data sets using JMP Clinical Medical writer has to review disparate data sources Not composed until patients complete study. Rate-limiting factor in completing the CSR. Changes to database may cause incorrect reporting; narrative text updated manually. The volume of events for severe diseases consume a great deal of resources Example Details Nicardipine trial (Haley et al., 1993) has 683 SAEs for 310 patients Sample narrative, which includes laboratory findings, has 409 words At 70 words-per-minute, it would take 5.8 minutes to write To write all narratives: 3991 minutes 67 hours 1.675 full-time equivalent What factors led to the event? What medications, evaluations or tests were associated with the event? Did the patient recover? What factors led to recovery? Was treatment related to the event? Did the patient complete the trial, or did the SAE cause the patient to discontinue the trial or interrupt study therapies?

Returning to the Example Efficient Safety Assessment in Clinical Trials Using the Computer-Generated AE Narratives of JMP Clinical Richard C. Zink & Drew Foglia JMP Life Sciences, SAS Institute Time Estimate Ignores JMP Clinical Narrative Dialog Time estimate ignores Comparing data sources Performing mental calculations Quality control Thinking and reflection Trips for coffee Bathroom breaks Narratives are extremely resource intensive! Dialogs to select narrative options SAS code and Velocity™ (project of the Apache® Software Foundation) templates to build the narrative text Returning to the Example 683 SAE narratives were generated in less than one minute Huge time savings compared to 1.675 FTE! CDISC! Narrative Dialog Subject-level analysis data set (ADSL) Adverse events (AE) Concomitant medications (CM) Demographics (DM) Disposition (DS) Study medication exposure (EX) Healthcare encounters (HO) Medical history (MH) Up to three findings domains, for example ECG test results (EG) Laboratory test results (LB) Vital signs (VS) Conclusions JMP Clinical AE Narratives Accelerates the writing process Improves quality control Allows for additional nuanced detail to be added by the medical writer, including JMP figures Table of contents, watermarks, images Focus on the science Guide appropriate management of patients

Subject-Level Narrative Event-Level Narrative with Tables Efficient Safety Assessment in Clinical Trials Using the Computer-Generated AE Narratives of JMP Clinical Richard C. Zink & Drew Foglia JMP Life Sciences, SAS Institute Subject-Level Narrative Translated Narrative Event-Level Narrative with Tables